86163-17-9

Basic information

• Product Name: (E)-5-(2-CARBOMETHOXYVINYL)-2'-DEOXYURIDINE
• Synonyms: (E)-5-(2-CARBOMETHOXYVINYL)-2'-DEOXYURIDINE;2-Propenoic acid,3-[1-(2-deoxy-b-D-erythro-pentofuranosyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyriMidinyl]-,Methyl ester, (2E)-
• CAS NO: 86163-17-9
• Molecular Formula: C₁₃H₁₆N₂O₇
• Molecular Weight: 312.28
• Mol File: 86163-17-9.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Density: 1.540±0.06 g/cm3(Predicted)
• Solubility: Acetone; Dichloromethane; DMSO
• PKA: 8.51±0.10(Predicted)
• CAS DataBase Reference: (E)-5-(2-CARBOMETHOXYVINYL)-2'-DEOXYURIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-5-(2-CARBOMETHOXYVINYL)-2'-DEOXYURIDINE(86163-17-9)
• EPA Substance Registry System: (E)-5-(2-CARBOMETHOXYVINYL)-2'-DEOXYURIDINE(86163-17-9)

Safety Data

• Hazardous Substances Data: 86163-17-9(Hazardous Substances Data)

Usage

Description

(E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine is a derivative of 5-(2-Hydroxyethyl)-2'-deoxyuridine (H942060), a novel and potent antiviral nucleoside analog with potential applications in the medical field.

Uses

Used in Antiviral Applications:
(E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine is used as an antiviral agent for its ability to inhibit viral replication and reduce the severity of viral infections. Its unique structure allows it to target specific viral enzymes, making it a promising candidate for the development of new antiviral therapies.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine is used as a key intermediate in the synthesis of antiviral drugs. Its unique chemical properties enable the development of innovative drug formulations with improved efficacy and safety profiles.
Used in Research and Development:
(E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine is also utilized in research and development for studying the mechanisms of viral infections and the development of resistance to antiviral drugs. Its use in laboratory settings contributes to a better understanding of viral diseases and the discovery of new treatment options.

Upstream product

• 951-78-0 2'-deoxyuridine 
• 292638-85-8 acrylic acid methyl ester 
• 54-42-2 5-Iodo-2'-deoxyuridine 
• 76772-94-6 5-Iodo-4-trimethylsilanyloxy-1-((2R,4S,5R)-4-trimethylsilanyloxy-5-trimethylsilanyloxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one 
• 611-53-0 5-Iodo-2'-deoxycytidine 
• 65505-76-2 5-chloromercuri-2'-deoxyuridine 

Downstream Products

• 74131-06-9 (E)-3-(1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acrylic acid 
• 96203-40-6 5'-O-[4,4'-dimethoxytrityl]-5-[3-methoxy-3-oxopropyl]-2'-deoxyuridine 
• 86214-06-4 (E)-5-(2-bromovinyl)-2'-deoxy-3-methyluridine 
• 91593-18-9 3',5'-di-O-acetyl-(E)-5-(2-bromovinyl)-2'-deoxyuridine 
• 84218-85-9 (E)-5-(2-bromovinyl)-2'-deoxy-5'-O-p-toluenesulphonyluridine 
• 114494-94-9 (E)-5-(2-bromovinyl)-2'-deoxy-5'-O-t-butyldiphenylsilyluridine 
• 114494-95-0 (E)-5-(2-bromovinyl)-2'-deoxy-3'-O-methyl-5'-O-t-butyldiphenylsilyluridine 
• 69304-47-8 (E)-5-(2-bromovinyl)-2'-deoxyuridine 

Relevant articles and documents

Nucleic acid probe, method for designing nucleic acid probe, and method for detecting target sequence

The present invention provides a nucleic acid probe that can achieve high detection sensitivity and high specificity in mutation detection, mismatch detection, etc. by the PCR method, a method for designing such a nucleic acid probe, and a method for detecting a target sequence. The nucleic acid probe includes a nucleic acid molecule, and the nucleic acid molecule includes a plurality of fluorescent dye moieties that exhibit an excitonic effect. At least two of the fluorescent dye moieties that exhibit an excitonic effect are bound to the same base or two adjacent bases in the nucleic acid molecule with each fluorescent dye moiety being bound via a linker (a linking atom or a linking atomic group). The extension-side end of the nucleic acid molecule is chemically modified, thereby preventing an extension reaction of the nucleic acid molecule.

ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites

Nucleosides represent a major chemotherapeutic class for treating cancer, however their limitations in terms of cellular uptake, nucleoside kinase-mediated activation and catabolism are well-documented. The monophosphate pro-nucleotides known as ProTides represents a powerful strategy for bypassing the dependence on active transport and nucleoside kinase-mediated activation. Herein, we report the structural tuning of BVdU ProTides. Forty six phosphoramidates were prepared and biologically evaluated against three different cancer cell lines; murine leukemia (L1210), human CD4+T-lymphocyte (CEM) and human cervical carcinoma (HeLa). Twenty-fold potency enhancement compared to BVdU was achieved against L1210 cells. Interestingly, a number of ProTides showed low micromolar activity against CEM and HeLa cells compared to the inactive parent BVdU. The ProTides showed poor, if any measurable toxicity to non-tumourigenic human lung fibroblast cell cultures. Separation of four pairs of the diastereoisomeric mixtures and comparison of their spectral properties, biological activities and enzymatic activation rate is reported.

COMPOUND, NUCLEIC ACID, METHOD FOR PRODUCING NUCLEIC ACID, AND KIT FOR PRODUCING NUCLEIC ACID

A compound is represented by the following formula (1), (2), or (3) (where, in the above formulae (1), (2), and (3), Z11 and Z12 independently have a fluorescent property and are an uncharged atomic group exhibiting an exciton effect).